Spero Therapeutics (SPRO) Receivables - Net (2023 - 2025)
Spero Therapeutics' Receivables - Net history spans 3 years, with the latest figure at $25.4 million for Q4 2025.
- For Q4 2025, Receivables - Net fell 48.66% year-over-year to $25.4 million; the TTM value through Dec 2025 reached $25.4 million, down 48.66%, while the annual FY2025 figure was $25.4 million, 48.66% down from the prior year.
- Receivables - Net reached $25.4 million in Q4 2025 per SPRO's latest filing, up from $868000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $50.8 million in Q2 2024 to a low of $868000.0 in Q3 2025.
- Average Receivables - Net over 3 years is $35.9 million, with a median of $49.2 million recorded in 2023.
- Peak YoY movement for Receivables - Net: rose 0.49% in 2024, then plummeted 98.28% in 2025.
- A 3-year view of Receivables - Net shows it stood at $49.2 million in 2023, then rose by 0.49% to $49.4 million in 2024, then crashed by 48.66% to $25.4 million in 2025.
- Per Business Quant, the three most recent readings for SPRO's Receivables - Net are $25.4 million (Q4 2025), $868000.0 (Q3 2025), and $24.5 million (Q2 2025).